Jana Vargova

Dr. Jana Vargova

Pavol Jozef Šafárik University in Košice, Faculty of Science, Institute of Biology and Ecology, Department of Cell Biology
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
EKEva Konkoľová
Eva Konkoľová
Monika HudáčováMonika Hudáčová
Monika Hudáčová
SHSlavka Hamulakova
Slavka Hamulakova
Rastislav JendželovskýRastislav Jendželovský
Rastislav Jendželovský
JVJana Vargova
Jana Vargova
Maria KozurkovaMaria Kozurkova
Maria Kozurkova
A549 human lung carcinoma cell lines were treated with a series of new drugs with both tacrine and coumarin pharmacophores (derivatives 1a–2c) in order to test the compounds’ ability to inhibit both cancer cell growth and topoisomerase I and II activity. The ability of human topoisomerase I (hTOPI) and II to relax supercoiled plasmid DNA in the presence of various concentrations of the tacrine-coumarin hybrid molecules was studied with agarose gel electrophoresis. The biological activities of the derivatives were studied using MTT assays, clonogenic assays, cell cycle analysis and quantification of cell number and viability. The content and localization of the derivatives in the cells were analysed using flow cytometry and confocal microscopy. All of the studied compounds were found to have inhibited topoisomerase I activity completely. The effect of the tacrine-coumarin hybrid compounds on cancer cells is likely to be dependent on the length of the chain between the tacrine and coumarin moieties (1c, 1d = tacrine-(CH2)8–9-coumarin). The most active of the tested compounds, derivatives 1c and 1d, both display longer chains.

1 January 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
PNPatrik Nunhart
Patrik Nunhart
EKEva Konkoľová
Eva Konkoľová
LJLadislav Janovec
Ladislav Janovec
Rastislav JendželovskýRastislav Jendželovský
Rastislav Jendželovský
JVJana Vargova
Jana Vargova
Maria KozurkovaMaria Kozurkova
Maria Kozurkova

1 January 2019 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
JJJana Janockova
Jana Janockova
Jan KorabecnyJan Korabecny
Jan Korabecny
JPJana Plsikova
Jana Plsikova
KBKaterina Babkova
Katerina Babkova
EKEva Konkoľová
Eva Konkoľová
Maria KozurkovaMaria Kozurkova
Maria Kozurkova
A combination of biochemical, biophysical and biological techniques was used to study calf thymus DNA interaction with newly synthesized 7-MEOTA-tacrine thiourea 12–17 and urea heterodimers 18–22, and to measure interference with type I and II topoisomerases. Their biological profile was also inspected in vitro on the HL-60 cell line using different flow cytometric techniques (cell cycle distribution, detection of mitochondrial membrane potential dissipation, and analysis of metabolic activity/viability). The compounds exhibited a profound inhibitory effect on topoisomerase activity (e.g. compound 22 inhibited type I topoisomerase at 1 µM concentration). The treatment of HL-60 cells with the studied compounds showed inhibition of cell growth especially with hybrids containing thiourea (14–17) and urea moieties (21 and 22). Moreover, treatment of human dermal fibroblasts with the studied compounds did not indicate significant cytotoxicity. The observed results suggest beneficial selectivity of the heterodimers as potential drugs to target cancer cells.

1 December 2013 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
LMLucia Mikešová
Lucia Mikešová
JMJaromir Mikes
Jaromir Mikes
JKJán Kovaľ
Ján Kovaľ
KGKatarína Gyurászová
Katarína Gyurászová
ĽČĽubomír Čulka
Ľubomír Čulka
PFPeter Fedoročko
Peter Fedoročko

17 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMartin Majerník
Martin Majerník
Rastislav JendželovskýRastislav Jendželovský
Rastislav Jendželovský
JVJana Vargova
Jana Vargova
ZJZuzana Jendzelovska
Zuzana Jendzelovska
PFPeter Fedoročko
Peter Fedoročko
It is more than sixty years since the era of modern photodynamic therapy (PDT) for cancer began. Enhanced selectivity for malignant cells with a reduced selectivity for non-malignant cells and good biocompatibility along with the limited occurrence of side effects are considered to be the most significant advantages of PDT in comparison with conventional therapeutic approaches, e.g., chemotherapy. The phenomenon of multidrug resistance, which is associated with drug efflux transporters, was originally identified in relation to the application of chemotherapy. Unfortunately, over the last thirty years, numerous papers have shown that many photosensitizers are the substrates of efflux transporters, significantly restricting the effectiveness of PDT. The concept of a dynamic nanoplatform offers a possible solution to minimize the multidrug resistance effect in cells affected by PDT. Indeed, recent findings have shown that the utilization of nanoparticles could significantly enhance the therapeutic efficacy of PDT. Additionally, multifunctional nanoplatforms could induce the synergistic effect of combined treatment regimens, such as PDT with chemotherapy. Moreover, the surface modifications that are associated with nanoparticle functionalization significantly improve the target potential of PDT or chemo-PDT in multidrug resistant and cancer stem cells.

1 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MBMarian Babincak
Marian Babincak
Rastislav JendželovskýRastislav Jendželovský
Rastislav Jendželovský
JKJán Košuth
Ján Košuth
MMMartin Majerník
Martin Majerník
JVJana Vargova
Jana Vargova
PFPeter Fedoročko
Peter Fedoročko
Skyrin (SKR) is a plant bisanthraquinone secondary metabolite from the Hypericum genus with potential use in anticancer therapy. However, its effect and mechanism of action are still unknown. The negative effect of SKR on HCT 116 and HT-29 cancer cell lines in hypoxic and normoxic conditions was observed. HCT 116 cells were more responsive to SKR treatment as demonstrated by decreased metabolic activity, cellularity and accumulation of cells in the G1 phase. Moreover, an increasing number of apoptotic cells was observed after treatment with SKR. Based on the LC-MS comparative proteomic data from hypoxia and normoxia (data are available via ProteomeXchange with the identifier PXD019995), SKR significantly upregulated Death receptor 5 (DR5), which was confirmed by real-time qualitative PCR (RT-qPCR). Furthermore, multiple changes in the Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-activated cascade were observed. Moreover, the reversion of TRAIL resistance was observed in HCT 116, HT-29 and SW620 cell lines, even in hypoxia, which was linked to the upregulation of DR5. In conclusion, our results propose the use of SKR as a prospective anticancer drug, particularly as an adjuvant to TRAIL-targeting treatment to reverse TRAIL resistance in hypoxia.